AKEEGA™ is the only FDA-approved medication that combines PARPi/NHT into a single dual action tablet1
Simplified dosing in a dual action tablet: two tablets, once daily1
The recommended AKEEGA™ dose is 200 mg niraparib/1,000 mg abiraterone acetate*
*AKEEGA™ is indicated with 10 mg prednisone daily.
AKEEGA™ offers two strengths for dosing flexibility and adjustments as needed1
AKEEGA™ recommended dose
200 mg/1,000 mg (niraparib/abiraterone acetate) orally once daily with prednisone 10 mg daily
AKEEGA™ reduced dose†
100 mg/1,000 mg (niraparib/abiraterone acetate) orally once daily with prednisone 10 mg daily
Tablets shown are not actual size.
†Please see full Prescribing Information for guidance on dosage modification for adverse reactions with AKEEGATM.
In the MAGNITUDE Study, AKEEGA™ demonstrated:
85% of BRCA+ mCRPC patients remained on AKEEGA™ without discontinuing due to TEAEs
72% of BRCA+ mCRPC patients did not need a dose reduction with AKEEGA™
50% of BRCA+ mCRPC patients remained on AKEEGA™ without interruption due to TEAEs
†Please see full Prescribing Information for guidance on dosage modification for adverse reactions with AKEEGATM.
The recommended dose of AKEEGA™ is 200 mg niraparib/1,000 mg abiraterone acetate (two 100 mg/500 mg tablets)*
AKEEGA™ tablets must be taken orally as a single dose once a day on an empty stomach
Patients should not eat food for at least 2 hours before and for at least 1 hour after taking AKEEGA™
The tablets must be swallowed whole with water. Advise patients not to crush or chew tablets
If a dose of AKEEGA™ or prednisone is missed, instruct patients to take the dose as soon as possible on the same day and to return to the normal schedule the following day
Extra tablets must not be taken to make up for the missed dose
Learn how your patients
can access AKEEGA™
See results from the MAGNITUDE trial
*AKEEGA™ is indicated with 10 mg prednisone daily. Patients receiving AKEEGA™ should also receive a GnRH analog concurrently or should have had a bilateral orchiectomy.1
†Please see full Prescribing Information for guidance on dosage modification for adverse reactions with AKEEGATM.
BRCA+ = BRCA gene-mutated; GnRH = gonadotropin-releasing hormone; mCRPC = metastatic castration-resistant prostate cancer; NHT = novel hormonal therapy; PARPi = poly (ADP-ribose) polymerase (PARP) inhibitor; TEAE = treatment-emergent adverse event.
Reference:
1. AKEEGA™ [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
